PureTech Health Plc
Research PureTech Health Plc (PRTC) on Bullrun: market cap USD 407.58M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPRTC
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 407.58M
- Financial periodFY2025
- RevenueUSD 4.66M
- Revenue growth8.0%
- Net income-USD 109.74M
- Free cash flow-USD 85.14M
Valuation Snapshot
latest market cap is USD 407.58M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.66M | -USD 109.74M | -USD 85.14M | n/a | -4.6 | USD 252.47M | USD 19.59M | USD 312.07M |
| FY2024 | USD 4.32M | USD 53.51M | -USD 134.38M | n/a | 2.1 | USD 280.64M | USD 22.36M | USD 414.71M |
| FY2023 | USD 750.00K | -USD 65.70M | -USD 106.16M | n/a | -2.4 | USD 191.08M | USD 25.34M | USD 464.07M |
| FY2022 | USD 2.09M | -USD 50.35M | -USD 180.97M | n/a | -0.5 | USD 149.87M | USD 46.87M | USD 542.22M |
| FY2021 | USD 9.98M | -USD 60.56M | -USD 163.94M | n/a | -6.7 | USD 465.71M | USD 52.75M | USD 593.52M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-06-04 | USD 407.58M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 401.55M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 441.97M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 766.08M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 888.63M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.06B | n/a | n/a | n/a |
About PureTech Health Plc
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is PureTech Health Plc's market cap?
PureTech Health Plc's market capitalization is USD 407.58M.
What does PureTech Health Plc do?
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions.